Media Archive
Search our media archive for news, events or related images on your topic.
| Content | |
|---|---|
Foto Bibliothek Tarceva 150 mg: for the treatment of advanced non-small cell lung and pancreatic cancermore | |
Foto Bibliothek Epidermal Growth Factor Receptor tyrosine kinase domain with 4-anilinoquinazoline inhibitor erlotinib (Tarceva). Surface ... more | |
| 13. Juli 2009 New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancer Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival ... more | |
| 30. Mai 2009 Maintenance treatment with Avastin and Tarceva in combination helps lung cancer patients live longer without their disease worsening more | |
| 03. Februar 2009 Avastin and Tarceva in combination significantly improves the time patients with advanced lung cancer can live without their disease worsening Roche today announced interim results from a phase III study (ATLAS) in patients with advanced non small cell lung cancer ... more | |
| 07. November 2008 Tarceva brings new hope to patients with advanced non-small cell lung cancer Roche today announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression ... more | |
| 06. Oktober 2008 Roche announces topline outcomes for Avastin-Tarceva combination study in advanced lung cancer Phase III data shows evidence of potential benefit for patients with advanced lung cancer. Roche today announced topline ... more | |
| Mediarelease, 2007/10/22 Tarceva approved for lung cancer in Japan Roche, Chugai and OSI Pharmaceuticals, Inc. announced today that Tarceva (erlotinib) has been approved in Japan for the treatment ... more | |
| Mediarelease, 2007/01/29 Tarceva : European approval for pancreatic cancer treatment more | |
| 15. December 2006 Tarceva receives positive EU opinion for the treatment of metastatic pancreatic cancer more | |
| 28. July 2006 In the interests of patients, Roche will consider all options following CHMP opinion on Tarceva in pancreatic cancer more | |
| 03. November 2005 Tarceva receives approval for pancreatic cancer in the United States more | |
| 21. September 2005 Tarceva approved in Europe for lung cancer more | |
| 27. June 2005 Tarceva receives positive opinion in EU for the treatment of patients with lung cancer more | |
| 02. May 2005 Tarceva - supplemental new drug application filed in the US for treatment of pancreatic cancer more | |
| 22. March 2005 New lung cancer medicine Tarceva receives first European approval more | |
| 19. November 2004 US approval for breakthrough lung cancer medicine Tarceva more | |
| 20. September 2004 Significant Survival Benefit for Breakthrough Drug Tarceva in Advanced Pancreatic Cancer Study shows a significant improvement in overall survival for patients given Tarceva combined with chemotherapy versus chemotherapy ... more | |
| 26. August 2004 New hope in fight against advanced lung cancer more | |
| 07. June 2004 Roche at ASCO: Important data underscore Roche's leading position in oncology more | |
| Mediarelease, 2004/04/26 New cancer drug Tarceva - a breakthrough with significant survival benefit in patients with advanced lung cancer more | |
| 01. October 2003 Phase III trials of Tarceva plus chemotherapy in lung cancer patients do not meet primary endpoint more |